Advertisement

Topics

Esophagectomy: Sweet Versus Ivor-Lewis

2014-08-27 03:16:45 | BioPortfolio

Summary

Esophageal carcinoma is an aggressive disease with a poor prognosis. Surgical resection remains the basic method of management of this malignancy. Although different approaches have been described for the surgical resection of esophageal cancer, there is no statistical evidence based on large scale prospective randomized trials with regard to the issue that which is the optimal surgical approach for esophageal cancer. The purpose of this study is to test two different approach of transthoracic esophagectomy (Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure and Left Side Thoracotomy Approach: Sweet Procedure) in middle or lower third intrathoracic esophageal cancer. This research is being done to see whether one approach is superior than the other approach with better long-term outcome and acceptable postoperative short-term outcome or not.

Description

Background :

Esophageal carcinoma is an aggressive disease with a poor prognosis. Surgical resection remains the basic method of management of this malignancy. Although different approaches have been described for the surgical resection of esophageal cancer, there is no statistical evidence based on large scale prospective randomized trials with regard to the issue that which is the optimal surgical approach for esophageal cancer. In middle or lower third intrathoracic esophageal cancer, a great number of thoracic surgeon preferred the Ivor-Lewis Procedure(Right Side Thoracotomy plus Midline Laparotomy Approach), and believe that this approach can get better exposure for the upper mediastinal node dissection so can get the better long-term survival. But some others preferred the Sweet Procedure(Left Side Thoracotomy Approach),especially in china, more than two of the third unit performed the left side approach esophagectomy routinely and the long-term survival was reported equal to even better than the right side approach. The purpose of this study is to conduct a large scale prospective randomized Phase Ⅲ clinical trial to test that based on the long-term outcomes(overall survival and disease free survival )and postoperative short-term outcomes(mortality, morbidity),whether one approach is superior than the other approach or not.

Objectives:

1. To compare overall survival after right side approach and left side approach esophagectomy

2. To compare locoregional recurrence, disease free survival after right side approach and left side approach esophagectomy

3. To compare postoperative morbidity and mortality in the two groups

4. To evaluate short and long term quality of life after the two procedures

Design: Prospective randomized controlled

Setting: Fudan University Cancer Center, Shanghai, China.

Patients and methods : All patients with biopsy proven carcinoma of the middle or lower third of the esophagus presenting to our hospital will be considered for the study.

Inclusion Criteria:

- Patients with histologically proven squamous cell esophageal cancer

- Patients with cT1-T3/N0-N1 mid or distal third (inferior to carina and 3cm superior to cardia ) operable esophageal lesion. Staging investigations including esophagogastroscopy, chest and abdominal CT scan, barium swallow and selective endoscopic ultrasonography showing no evidence of invading adjacent structure such as spine, bronchus, pericardium , descending aorta and without enlargement cervical and celiac nodes (diameter of short axis greater than 1.5cm) measured at CT scans.

- Karnofsky performance status greater than or equal to 80%

- Pulmonary and cardiac function must be acceptable for surgery according to institutional standards.

- Acceptable hepatic, renal and bone marrow function.

Exclusion Criteria:

- Patients with low performance status(Karnofsky score <80%)

- Past history of malignancy

- Stage investigations indicating unresectable advanced disease(T4 or M1a,M1b)

- Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment

- Patients medically unfit for surgical resection

- Patients with pulmonary reserve inadequate to undergo thoracotomy and extensive mediastinal lymphadenectomy.

- Patients with a significant history of unstable cardiovascular disease that in the opinion of the treating physician should preclude the patient from protocol treatment.

- Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.

- Significant psychiatric illness that would interfere with patient compliance

- Patients with severe hepatic cirrhosis or with serious renal disease unacceptable for surgery

- Patients considered of salvage surgery after definitive chemoradiotherapy

- Patients after neoadjuvant chemoradiotherapy

- Patients above the age of 75 years

- Patients unreliable for follow up

Staging investigations will be standard and will include

1. Computed Tomography (CT) scans in all patients

2. Esophagogastroscopy

3. Barium swallow

4. Endoscopic Ultrasonography (EUS) wherever possible

5. PET-CT scan wherever possible

Randomization:

Block randomization will be done using a computer generated sheet. Randomization will be performed 3 days to 1 week before the operation.

All surgeries will be performed under general anesthesia with epidural analgesia. The surgery will be either performed by or under the direct supervision of consultant thoracic surgeons with experience in esophageal surgery. Operative time, blood loss, blood product replacement and all intraoperative details will be recorded in the proforma. Patients will be shifted postoperatively to the intensive care unit (ICU) for observation and subsequently to the recovery or high dependency ward once stabilized. Postoperative details including period of postoperative ventilation, hemorrhage, pulmonary and cardiac complications, arrhythmias, thoracic duct leak, anastomotic leak, wound infection and recurrent laryngeal nerve paresis or palsy will be recorded. Postoperative mortality will be defined as 30-day mortality plus death before discharge after surgery. The total duration of ICU stay and hospital stay will also be recorded.

Follow up:

Patients will be followed up three monthly for the first two years and six monthly for the third to fifth years and annually thereafter. A detailed history and clinical examination and CT scan, barium swallow and ultrasound will be done routinely on every follow up.

Data management: All collected data will be entered into a statistical software package for subsequent analysis

Main research variables:

Primary end point: Disease free survival in the two arms

Secondary endpoints:

1. Overall survival

2. Locoregional recurrence

3. Postoperative morbidity and mortality

4. Quality of life : assessed with EORTC QLQ-C30 scale and EORTC QLQ- OES18 scale.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Esophageal Neoplasms

Intervention

Esophagectomy

Location

Fudan University Cancer Center
Shanghai
Shanghai
China
200032

Status

Not yet recruiting

Source

Fudan University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:16:45-0400

Clinical Trials [606 Associated Clinical Trials listed on BioPortfolio]

Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer – Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)

A multicenter randomized comparison of primary esophagectomy against definitive chemoradiotherapy for the treatment of squamous esophageal cancer.

A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer

The purpose of this study is to test 2 different methods of surgery to remove cancer in the esophagus. This research is being done to see whether removing more tissue and lymph nodes sur...

Endoscopic Evaluation After Esophagectomy

Gastric conduit ischemia or anastomotic breakdown after esophagectomy with cervical esophagogastrostomy often cause severe complications, such as leakage, necrotic organs, and strictures. ...

Endoscopic Evaluation for Predicting the Complications Related to Gastric Conduit After Esophagectomy

Gastric conduit ischemia or anastomotic breakdown after esophagectomy with cervical esophagogastrostomy often cause severe complications, such as leakage, necrotic organs, and strictures. ...

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy. ...

PubMed Articles [1084 Associated PubMed Articles listed on BioPortfolio]

Standardizing procedures improves and homogenizes short-term outcomes after minimally invasive esophagectomy.

Esophageal cancer is one of the deadliest cancers worldwide. Esophagectomy with lymphadenectomy is regarded as the only curative option for resectable esophageal cancer, but it is associated with high...

Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer.

Evidence suggests that minimally invasive esophagectomy has several advantages with regard to short-term outcomes, compared to open esophagectomy in esophageal cancer patients. However, the impact of ...

Clinical Importance of Mean Corpuscular Volume as a Prognostic Marker After Esophagectomy for Esophageal Cancer: A Retrospective Study.

To elucidate the clinical value of mean corpuscular volume (MCV) for prognostic prediction in patients with esophageal cancer who underwent radical esophagectomy.

Salvage esophagectomy with pancreatectomy for local recurrence of thoracic esophageal cancer after definitive chemoradiotherapy: A case report.

We encountered a case of advanced thoracic esophageal cancer in which R0 resection was achieved by salvage esophagectomy with pancreatectomy, but relapse occurred in the early postoperative phase.

Recent Advances in Minimally Invasive Esophagectomy.

The treatment of esophageal cancer has become more effective due to advances in surgical techniques, multidisciplinary approach, appropriate use of neoadjuvant therapy and perioperative care at center...

Medical and Biotech [MESH] Definitions

Tumors or cancer of the ESOPHAGUS.

A pathological condition characterized by the presence of a number of ESOPHAGEAL DIVERTICULA in the ESOPHAGUS.

Circular innermost layer of the ESOPHAGUS wall that mediates esophageal PERISTALSIS which pushes ingested food bolus toward the stomach.

Excision of part (partial) or all (total) of the esophagus. (Dorland, 28th ed)

A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.

More From BioPortfolio on "Esophagectomy: Sweet Versus Ivor-Lewis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Trial